Fairvalue-Calculator Fairvalue-Calculator
EN DE

Puriblood Medical Co (6847) Fair Value & Analysis

Healthcare · TW · Market cap 1.2B TWD

Price76.60 TWD
Fair Value29.56 TWD
Upside-61.4%
Quality95/100
Evidence: Low Range 22.17 TWD – 36.95 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Puriblood Medical Co (6847) currently trades at 76.60 TWD, while our model-based Fair Value estimate is 29.56 TWD — implying the stock looks roughly 61.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -96% Danaher Corporation (DHR) -52% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -66% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -54%

Frequently asked questions

Is Puriblood Medical Co (6847) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 29.56 TWD versus a price of 76.60 TWD — about −61% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6847?
Our 21-model fair value for Puriblood Medical Co is 29.56 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 76.60 TWD.
What is the quality score of 6847?
Puriblood Medical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.